HomeCompareCLBS vs VIG

CLBS vs VIG: Dividend Comparison 2026

CLBS yields 131.33% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLBS wins by $12.96M in total portfolio value
10 years
CLBS
CLBS
● Live price
131.33%
Share price
$0.43
Annual div
$0.56
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.99M
Annual income
$5,201,713.69
Full CLBS calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — CLBS vs VIG

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLBSVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLBS + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLBS pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS
Annual income on $10K today (after 15% tax)
$11,163.23/yr
After 10yr DRIP, annual income (after tax)
$4,421,456.64/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, CLBS beats the other by $4,421,304.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + VIG for your $10,000?

CLBS: 50%VIG: 50%
100% VIG50/50100% CLBS
Portfolio after 10yr
$6.51M
Annual income
$2,600,946.42/yr
Blended yield
39.94%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys
0
VIG buys
0
No recent congressional trades found for CLBS or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLBSVIG
Forward yield131.33%1.64%
Annual dividend / share$0.56$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$12.99M$32.4K
Annual income after 10y$5,201,713.69$179.15
Total dividends collected$11.90M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CLBS vs VIG ($10,000, DRIP)

YearCLBS PortfolioCLBS Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$23,833$13,133.21$11,304$163.92+$12.5KCLBS
2$54,754$29,252.94$12,759$166.33+$42.0KCLBS
3$121,396$62,809.15$14,382$168.52+$107.0KCLBS
4$260,039$130,144.39$16,192$170.52+$243.8KCLBS
5$538,781$260,539.45$18,210$172.34+$520.6KCLBS
6$1,080,999$504,503.28$20,460$173.98+$1.06MCLBS
7$2,102,673$946,004.75$22,968$175.48+$2.08MCLBS
8$3,969,574$1,719,713.85$25,763$176.83+$3.94MCLBS
9$7,281,647$3,034,202.37$28,878$178.05+$7.25MCLBS
10$12,993,076$5,201,713.69$32,350$179.15+$12.96MCLBS

CLBS vs VIG: Complete Analysis 2026

CLBSStock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this CLBS vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHDCLBS vs JEPICLBS vs OCLBS vs KOCLBS vs MAINCLBS vs DGROCLBS vs NOBLCLBS vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.